Patients with the diagnosis of relapsing remitting multiple sclerosis or a clinically isolated syndrome.

Patients must be on treatment with Betaferon or the decision to treat patients with Betaferon has been made by the attending physician.

Patient and attending physicians must have agreed on the usage of the BETACONNECT auto-injector device

Written informed consent must be obtained.

BAY86-5046 (Betaseron), Non Interventional Studies